UBC9 knockdown inhibits the proliferation and migration of osteosarcoma cells and markedly increases the sensitivity of these cells to the combination treatment of herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV) [143]. Here, UBE2I is linked to osteosarcoma.